Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma?

Saboor Khan, Guido Sclabas, Kaye Reid-Lombardo, Michael G. Sarr, David Nagorney, Michael L. Kendrick, Florencia Que, John H. Donohue, Marianne Huebner, Christine Lohse, Michael B. Farnell

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. Methods: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. Results: Of the 586 consecutive patients studied, there were 232 (39.6%) with BMI <25, 232 (39.6%) with BMI 25 to <30, 89 (15.2%) with BMI 30 to <35, and 33 (5.6%) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P = 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. Conclusions: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.

Original languageEnglish (US)
Pages (from-to)1820-1825
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume14
Issue number11
DOIs
StatePublished - 2010

Fingerprint

Pancreaticoduodenectomy
Morbid Obesity
Adenocarcinoma
Body Mass Index
Lymph Nodes
Pancreatic Neoplasms
Obesity
Neoplasms
Chi-Square Distribution
Hospital Mortality
Disease-Free Survival

Keywords

  • BMI
  • Pancreatic cancer
  • Pancreatic surgery
  • Pancreatoduodenectomy
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma? / Khan, Saboor; Sclabas, Guido; Reid-Lombardo, Kaye; Sarr, Michael G.; Nagorney, David; Kendrick, Michael L.; Que, Florencia; Donohue, John H.; Huebner, Marianne; Lohse, Christine; Farnell, Michael B.

In: Journal of Gastrointestinal Surgery, Vol. 14, No. 11, 2010, p. 1820-1825.

Research output: Contribution to journalArticle

Khan, S, Sclabas, G, Reid-Lombardo, K, Sarr, MG, Nagorney, D, Kendrick, ML, Que, F, Donohue, JH, Huebner, M, Lohse, C & Farnell, MB 2010, 'Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma?', Journal of Gastrointestinal Surgery, vol. 14, no. 11, pp. 1820-1825. https://doi.org/10.1007/s11605-010-1285-9
Khan, Saboor ; Sclabas, Guido ; Reid-Lombardo, Kaye ; Sarr, Michael G. ; Nagorney, David ; Kendrick, Michael L. ; Que, Florencia ; Donohue, John H. ; Huebner, Marianne ; Lohse, Christine ; Farnell, Michael B. / Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma?. In: Journal of Gastrointestinal Surgery. 2010 ; Vol. 14, No. 11. pp. 1820-1825.
@article{01b95f0c40ee423db83ba95a3a4573d5,
title = "Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma?",
abstract = "Introduction: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. Methods: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. Results: Of the 586 consecutive patients studied, there were 232 (39.6{\%}) with BMI <25, 232 (39.6{\%}) with BMI 25 to <30, 89 (15.2{\%}) with BMI 30 to <35, and 33 (5.6{\%}) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P = 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. Conclusions: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.",
keywords = "BMI, Pancreatic cancer, Pancreatic surgery, Pancreatoduodenectomy, Survival",
author = "Saboor Khan and Guido Sclabas and Kaye Reid-Lombardo and Sarr, {Michael G.} and David Nagorney and Kendrick, {Michael L.} and Florencia Que and Donohue, {John H.} and Marianne Huebner and Christine Lohse and Farnell, {Michael B.}",
year = "2010",
doi = "10.1007/s11605-010-1285-9",
language = "English (US)",
volume = "14",
pages = "1820--1825",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Does Body Mass Index/Morbid Obesity Influence Outcome in Patients Who Undergo Pancreatoduodenectomy for Pancreatic Adenocarcinoma?

AU - Khan, Saboor

AU - Sclabas, Guido

AU - Reid-Lombardo, Kaye

AU - Sarr, Michael G.

AU - Nagorney, David

AU - Kendrick, Michael L.

AU - Que, Florencia

AU - Donohue, John H.

AU - Huebner, Marianne

AU - Lohse, Christine

AU - Farnell, Michael B.

PY - 2010

Y1 - 2010

N2 - Introduction: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. Methods: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. Results: Of the 586 consecutive patients studied, there were 232 (39.6%) with BMI <25, 232 (39.6%) with BMI 25 to <30, 89 (15.2%) with BMI 30 to <35, and 33 (5.6%) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P = 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. Conclusions: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.

AB - Introduction: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. Methods: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. Results: Of the 586 consecutive patients studied, there were 232 (39.6%) with BMI <25, 232 (39.6%) with BMI 25 to <30, 89 (15.2%) with BMI 30 to <35, and 33 (5.6%) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P = 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. Conclusions: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.

KW - BMI

KW - Pancreatic cancer

KW - Pancreatic surgery

KW - Pancreatoduodenectomy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77958473897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958473897&partnerID=8YFLogxK

U2 - 10.1007/s11605-010-1285-9

DO - 10.1007/s11605-010-1285-9

M3 - Article

C2 - 20676790

AN - SCOPUS:77958473897

VL - 14

SP - 1820

EP - 1825

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -